Dear Reader,

As we reach the final issue of Drugs—Real World Outcomes for 2019, we wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content.

2019 was a successful year for Drugs—Real World Outcomes. Over 20 articles have been published; the most popular of these, in terms of downloads from SpringerLink, have been:

  • Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study. Oshikoya, K.A., Carroll, R., Aka, I. et al. Drugs—Real World Outcomes (2019) 6: 59. https://doi.org/10.1007/s40801-019-0151-7

  • Patterns of High-Dose and Long-Term Proton Pump Inhibitor Use: A Cross-Sectional Study in Six South Australian Residential Aged Care Services. Hendrix, I., Page, A.T., Korhonen, M.J. et al. Drugs—Real World Outcomes (2019) 6: 105. https://doi.org/10.1007/s40801-019-0157-1

  • Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study. Sakata, Y., Matsuoka, T., Ohashi, S. et al. Drugs—Real World Outcomes (2019) 6: 27. https://doi.org/10.1007/s40801-019-0150-8

  • Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review. Joshi, R., Latremouille-Viau, D., Meiselbach, M.K. et al. Drugs—Real World Outcomes (2019) 6: 1. https://doi.org/10.1007/s40801-018-0146-9

  • A Benefit Risk Review of Pediatric Use of Hydrocodone/Chlorpheniramine, a Prescription Opioid Antitussive Agent for the Treatment of Cough. Sloan, V.S., Jones, A., Maduka, C. et al. Drugs—Real World Outcomes (2019) 6: 47. https://doi.org/10.1007/s40801-019-0152-6

  • Epidemiological Profile of Drug Overdose Reported in South-East Morocco from 2004 to 2016. Azekour, K., Belamalem, S., Soulaymani, A. et al. Drugs—Real World Outcomes (2019) 6: 11. https://doi.org/10.1007/s40801-019-0148-2

  • Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study. Lin, HM.D., Lai, CL., Dong, YH. et al. Drugs—Real World Outcomes (2019) 6: 93. https://doi.org/10.1007/s40801-019-0156-2

  • PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice. Parhofer, K.G., von Stritzky, B., Pietschmann, N. et al. Drugs—Real World Outcomes (2019) 6: 115. https://doi.org/10.1007/s40801-019-0158-0


We thank the authors who have contributed articles to Drugs—Real World Outcomes over the course of 2019. The skill and dedication of all authors are critical to the continued publication of the journal. The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for Drugs—Real World Outcomes in the last 12 months:

Anabela Barcelos, Portugal

Francisco Batel-Marques, Portugal

Marc Buyse, Belgium

Pia Caduff-Janosa, Sweden

Camilla Callegari, Italy

Antonio Clavenna, Italy

Jacqueline Corrigan-Curay, USA

Benjamin Daniels, Australia

Roni P. Dodiuk-Gad, Israel

Khalid Eljaaly, Saudi Arabia

Andrea Fagiolini, Italy

Filipa Farinha, UK

Nicola Ferri, Italy

Daniel Fife, USA

Meghan Gabriel, USA

Armando Gonzalez-Ruiz, UK

Kaushik Guha, UK

Jan Hasselstrom, Sweden

Benjamin Hohlfelder, USA

Laurence G. Howes, Australia

Magnus Ingelman-Sundberg, Sweden

Aditi Kadakia, USA

Emily Karanges, Australia

Abhishek Kavati, USA

Farzin Khosrow-Khavar, Canada

Shunsuke Kiuchi, Japan

Roger Knaggs, UK

Eitaro Kodani, Japan

Georgios D. Kotzalidis, Italy

Gilles Lambert, France

Kathryn Lang, USA

Marie Linder, Sweden

Jette Möller, Sweden

Lubov Matchekhina, Russia

Dídac Mauricio, Spain

Omid Mehrpour, Iran

Jose J. Mira, Spain

Pablo Mora, USA

Takatoshi Nawa, Japan

Khac-Dung Nguyen, France

Alexandra C. Pacurariu, The Netherlands

Vidhya Parameswaran, Canada

Klaus G. Parhofer, Germany

Wolfgang Philipp-Dormston, Germany

Sonam Puri, USA

Dima M. Qato, USA

Concetta Rafaniello, Italy

Lorenza Rimassa, Italy

Julie Rouette, Canada

Rafael Santana-Davila, USA

John D. Seeger, USA

Darshini Shah, USA

Michael D. Shapiro, USA

Caroline Sirois, Canada

Giuseppe Sito, Italy

Liberata Sportiello, Italy

Hema Sundaram, USA

Wade Thompson, Denmark

Sermin Toto, Germany

Joachim Veith, USA

Sigurd Vitols, Sweden

Kristie R. Weir, Australia

Dahlia Weitzman, Israel

Mike Wilcock, UK

Richard Willke, USA

Antoinette Wozniak, USA

Srikanth Yandrapalli, USA

Shan Yin, USA

Kazuki Yoshida, USA

Ulrich M. Zanger, Germany

In addition, we would like to thank the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:


G.C. Alexander, Johns Hopkins University, Baltimore, MD, USA

A. Beresniak, Data Mining International, Geneva, Switzerland

H. Birnbaum, Analysis Group, Inc., Boston, MA, USA

J. Bottomley, Amygdala Ltd., Letchworth Garden City, England

P. Denig, University of Groningen, Groningen, The Netherlands

J.E. Fincham, Presbyterian College School of Pharmacy, Clinton, SC, USA

B. Godman, Karolinska Institutet, Stockholm, Sweden

D. Goldsmith, Goldsmith Pharmacovigilance and Systems, New York, NY, USA

S. Karve, AbbVie, Chicago, IL, USA

C. Kozma, CK Consulting Associates, St. Helena Island, SC, USA

T. Lasky, U.S. Food and Drug Administration, Silver Spring, MD, USA

A.A. Mangoni, Flinders University, Adelaide, SA, Australia

S. Mimica-Matanovic, University Hospital Osijek, Osijek, Croatia

P.G. Parmar, Auckland University of Technology, Auckland, New Zealand

B. Rinaldi, University of Capania Luigi Vanvitelli, Naples, Italy

J.K. Sluggett, Monash University, Parkville, VIC, Australia

K.A. Swanson, University of Oklahoma, Oklahoma City, OK, USA

F. van Hunsel, The Netherlands Pharmacovigilance Centre Lareb, Brabant, The Netherlands

J.E Ware Jr., John Ware Research Group Incorporated, Watertown, MA, USA

Q. Zou, Medstar Health Research Institute, Washington, DC, USA

We do hope that you have found the articles published throughout the year in Drugs—Real World Outcomes to be interesting and informative. The editorial schedule for 2020 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year.


With best wishes

Dene Peters (Editor) and Kathy Fraser (Deputy Editor)